Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
ZENHOREN, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 9%, Oct-Dec Ordinary Profit Increases by 7.3 times
5845 ZENHOREN CO.,LTD. 【J-GAAP】
Earnings ReportZENHOREN CO.,LTD. <5845> [TSE Std] announced its financial results after the market closed on February 14th (18:00). The ordinary profit (non-consolidated) for the cumulative third quarter of the fiscal year ending March 2025 (April to December) increased 9.1% from the same period last year, reaching 1.99 billion yen. The progress rate toward the full-year plan of 2.37 billion yen was 83.9%, almost the same as the same period of the previous year of 83.4%.
Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the ordinary profit for the January to March period (4Q) is expected to grow 4.7% from the same period last year, reaching 0.38 billion yen.
In the most recent three-month period, from October to December (3Q), the ordinary profit surged 7.3 times that of the same period last year, reaching 0.77 billion yen. The operating profit margin drastically improved from 1.9% in the same period last year to 12.0%.
Kabutan News
Actual Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Apr - Dec, 2023 | 18,279 | 1,863 | 1,825 | 1,253 | 63.7 | 83.4 | Feb 14, 2024 | J-GAAP |
Apr - Dec, 2024 | 19,182 | 2,006 | 1,991 | 1,371 | 58.0 | 83.9 | Feb 14, 2025 | J-GAAP |
YoY | +4.9% | +7.7% | +9.1% | +9.4% | -9.0% |
Current Period Guidance
Second Half Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Oct - Mar, 2023 | 12,336 | 475 | 470 | 352 | 17.4 | 30 | May 15, 2024 | J-GAAP |
Oct - Mar, 2024 Guidance | 13,290 | 1,169 | 1,154 | 786 | 30.3 | 30 | Nov 14, 2024 | J-GAAP |
YoY | +7.7% | +146.1% | +145.5% | +123.3% | +73.9% |
Current Period Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar, 2024 | 24,510 | 2,224 | 2,189 | 1,538 | 76.1 | 30 | May 15, 2024 | J-GAAP |
Mar, 2025 Guidance | 26,021 | 2,403 | 2,372 | 1,623 | 62.5 | 30 | May 15, 2024 | J-GAAP |
YoY | +6.2% | +8.0% | +8.4% | +5.5% | -17.9% |
Quarterly Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Oct - Dec, 2023 | 6,105 | 114 | 106 | 67 | 3.4 | 1.9 | Feb 14, 2024 | J-GAAP |
Jan - Mar, 2024 | 6,231 | 361 | 364 | 285 | 14.1 | 5.8 | May 15, 2024 | J-GAAP |
Apr - Jun, 2024 | 6,356 | 696 | 688 | 474 | 20.9 | 11.0 | Aug 14, 2024 | J-GAAP |
Jul - Sep, 2024 | 6,375 | 538 | 530 | 363 | 15.9 | 8.4 | Nov 14, 2024 | J-GAAP |
Oct - Dec, 2024 | 6,451 | 772 | 773 | 534 | 22.6 | 12.0 | Feb 14, 2025 | J-GAAP |
YoY | +5.7% | +577.2% | +629.2% | +697.0% | +562.5% |
Related Articles
CAREER, Oct-Dec (1Q) Ordinary Profit Decreases by 74%
Aeria, Last Fiscal Year'sOrdinary ProfitExceeds Expectations, Returning to Profitability This Year
New Constructors Net, Apr-Dec (Cumulative 3Q) Ordinary Profit Turns to Profit, Oct-Dec Ordinary Profit Turns to Profit
Abalance, Undisclosed Ordinary Profit to Reach 5.1 billion yen for The Current Fiscal Year
Accrete, 47% Increase in Ordinary Profit for The Current Fiscal Year
ProjectHoldings, Break Evenin Ordinary Profit for The Current Fiscal Year
NAKAYO, Postponed Dividend for This Fiscal Year
f-code, 42% Increase in Net Income, Update Record High for Third Consecutive Term
Noile-Immune Biotech, Last Fiscal Year's Ordinary Profit Loss Narrows, Current period performance is undisclosed.
AEON Fantasy, The Current Fiscal Year Net Income Revised Downward to a Loss, Dividend Revised down by 5 yen